The European Medicines Agency has recommended for EU-wide approval 13 new medicines, including two orphans - Global Blood Therapeutics’ first-in-class therapy for sickle cell disease Oxbryta (voxelotor), and Pfizer/Opko Health’s treatment for growth hormone deficiency Ngenla (somatrogon).
The EMA has also recommended for pan-EU approval ObsEva’s Yselty (linzagolix choline), which the company says is a first-of-its-kind drug for uterine fibroids. Also, it adopted a negative opinion...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?